A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer

This study is currently recruiting participants.
Verified April 2014 by Eli Lilly and Company
Sponsor:
Information provided by (Responsible Party):
Eli Lilly and Company
ClinicalTrials.gov Identifier:
NCT01373164
First received: June 9, 2011
Last updated: April 10, 2014
Last verified: April 2014

June 9, 2011
April 10, 2014
July 2012
March 2015   (final data collection date for primary outcome measure)
  • Phase 1b: Recommended Phase 2 dose [ Time Frame: Time of first phase 1b dose until time of last phase 1b dose (approximately 1 year) ] [ Designated as safety issue: Yes ]
  • Phase 2: Overall Survival (OS) [ Time Frame: Baseline to date of death from any cause (approximately 2 year) ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT01373164 on ClinicalTrials.gov Archive Site
  • Phase 1b: Pharmacokinetics: Area under the plasma concentration versus time curve (AUC) [ Time Frame: Cycle 1 Days 1, 7, and 14 (predose; 0.5, 2, 3, and 6 hours post dose); Cycle 1 Days 15 and 16 (predose); Cycles 2- 3 Day 1 (predose) ] [ Designated as safety issue: Yes ]
  • Phase 1b: Pharmacokinetics: maximum plasma drug concentration (Cmax) [ Time Frame: Cycle 1 Days 1, 7, and 14 (predose; 0.5, 2, 3, and 6 hours post dose); Cycle 1 Days 15 and 16 (predose); Cycles 2- 3 Day 1 (predose) ] [ Designated as safety issue: Yes ]
  • Phase 1b: Number of participants with tumor response [ Time Frame: Baseline to end of Phase 1b (approximately 1 year) ] [ Designated as safety issue: No ]
  • Phase 2: Progression Free Survival [ Time Frame: Baseline to first date of progressive disease or death due to any cause (approximately 2 year) ] [ Designated as safety issue: Yes ]
  • Phase 2: Percentage change from baseline in tumor size (CTS) [ Time Frame: Baseline, end of Cycle 2 ] [ Designated as safety issue: No ]
  • Phase 2: Percentage of participants with a Tumor response, (Overall Response Rate [ORR]) [ Time Frame: Baseline to measured progressive disease (approximately 2 year) ] [ Designated as safety issue: No ]
  • Phase 2: Pharmacokinetics: AUC [ Time Frame: Cycle 1 Days 1 and 14, (predose; 0.5 to 2 hours, 3.5 to 5 hours post dose); Cycle 1 Day 7 (predose; 0.5 to 2 hours postdose); Cycle 1 Day 15, morning; Cycle 1 Day 16, morning ] [ Designated as safety issue: Yes ]
  • Phase 2: Pharmacokinetics: Cmax [ Time Frame: Cycle 1 Days 1 and 14, (predose; 0.5 to 2 hours, 3.5 to 5 hours post dose); Cycle 1 Day 7 (predose; 0.5 to 2 hours postdose); Cycle 1 Day 15, morning; Cycle 1 Day 16, morning ] [ Designated as safety issue: Yes ]
  • Phase 2: Change from baseline in Brief Pain Inventory-short form (BPI-sf) at study completion [ Time Frame: Baseline, study treatment completion (approximately 1 year) ] [ Designated as safety issue: No ]
  • Phase 2: Change from baseline in carbohydrate antigen 19.9 (CA19-9) level at first study completion follow-up [ Time Frame: Baseline, study treatment completion after first follow up visit (approximately 1 year) ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer
A Phase 1b/2 Study With Gemcitabine and LY2157299 for Patients With Metastatic Cancer (Phase 1b) and Advanced or Metastatic Unresectable Pancreatic Cancer (Phase 2)

Phase 1b: To determine the safe and tolerable dose of LY2157299 in combination with gemcitabine in patients with solid malignancy

Phase 2a: To compare the overall survival (OS) of patients with Stage II to IV unresectable pancreatic cancer when treated with a combination of LY2157299 and gemcitabine with that of gemcitabine plus placebo.

Not Provided
Interventional
Phase 1
Phase 2
Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Neoplasms
  • Neoplasm Metastasis
  • Pancreatic Cancer
  • Drug: LY2157299

    Administered orally twice daily for 14 days followed by 14 days of rest. Dose escalation will proceed if none of the first 3 participants experience a dose limiting toxicity (DLT) during the first cycle of treatment. If 1 of 3 participants experiences a DLT, the cohort will be expanded to include an additional 3 participants. If 2 or more participants experience a DLT, then the sponsor and investigator will jointly decide whether to reduce the dose to 20 mg BID for Cohort 1 or recruit into an additional cohort at an intermediate dose for Cohorts 2 and 3.

    Phase 2 recommended dose will be based on review of overall toxicity, dose reductions, omissions, and pharmacokinetic information from Phase 1b Cohorts. Dose will be administered orally twice daily for 14 days followed by 14 days of rest.

  • Drug: Gemcitabine
    Administered intravenously once per week for 7 weeks followed by a week of rest and then once per week for 3 weeks of every 4 weeks.
    Other Names:
    • Gemzar
    • LY188011
  • Drug: Placebo
    Administered orally twice daily for 14 days followed by 14 days of rest.
  • Experimental: Phase 1b: 80 mg LY2157299 + Gemcitabine

    Cohort 1: 40 mg LY2157299 is administered orally twice daily (BID) for 14 days followed by 14 days of rest (28 day cycle).

    Gemcitabine at a dose of 1000 mg/m^2 will be administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks.

    Interventions:
    • Drug: LY2157299
    • Drug: Gemcitabine
  • Experimental: Phase 1b: 160 mg LY2157299 + Gemcitabine

    Cohort 2: 80 mg LY2157299 is administered orally twice daily for 14 days followed by 14 days of rest (28 day cycle).

    Gemcitabine at a dose of 1000 mg/m^2 will be administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks.

    Interventions:
    • Drug: LY2157299
    • Drug: Gemcitabine
  • Experimental: Phase 1b: 300 mg LY2157299 + Gemcitabine

    Cohort 3: 150 mg LY2157299 is administered orally twice daily for 14 days followed by 14 days of rest (28 day cycle).

    Gemcitabine at a dose of 1000 mg/m^2 will be administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks.

    Interventions:
    • Drug: LY2157299
    • Drug: Gemcitabine
  • Experimental: Phase 2: Recomended dose of LY2157299 + Gemcitabine

    LY2157299 recommended dose determined from phase 1, administered orally twice daily for 14 days followed by 14 days of rest (28 day cycle).

    Gemcitabine at a dose of 1000 mg/m^2 will be administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks. Participant's may continue until disease progression, unacceptable toxicity, or another withdrawal criterion is met.

    Interventions:
    • Drug: LY2157299
    • Drug: Gemcitabine
  • Experimental: Phase 2: Placebo + Gemcitabine

    Placebo administered orally twice daily for 14 days followed 14 days of rest (28 day cycle).

    Gemcitabine at a dose of 1000 mg/m^2 will be administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks. Participant's may continue until disease progression, unacceptable toxicity, or another withdrawal criterion is met.

    Interventions:
    • Drug: Gemcitabine
    • Drug: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
168
March 2015
March 2015   (final data collection date for primary outcome measure)

Inclusion Criteria: For both Phase 1b and Phase 2 (unless specified in the following), patients are eligible to be included in the study only if they meet all of the following criteria:

For Phase 1b:

  • Have histological or cytological evidence of a diagnosis of cancer that is advanced and/or metastatic disease; that is refractory to standard therapy and/or therapies known to provide clinical benefit or for which no standard therapy exists; and/or in which gemcitabine therapy at the proposed doses and schedule would be considered appropriate treatment for the metastatic disease (eg, pancreatic cancer)
  • Patients may have received prior chemotherapy, radiotherapy, cancer-related hormone therapy, or other investigational therapy as treatment. There is no limit in the number of previous lines of therapy.

For Phase 1b and Phase 2:

  • Have measurable disease or non-measurable disease, defined according to Response Evaluation Criteria In Solid Tumors (RECIST)
  • Have given written informed consent prior to any study-specific procedures
  • Have adequate organ function including: Hematologic: absolute neutrophil count (ANC) greater than or equal to 1.5 x 10^9/L, platelets greater than or equal to 100 x 10^9/L, and hemoglobin greater than or equal to 9 g/dL. Hepatic: bilirubin less than or equal to 1.5 times upper limit of normal (ULN), and alkaline phosphatase (ALP), aspartate aminotransferase (AST), alanine aminotransferase (ALT)less than or equal to 2.5 times ULN. If the liver has tumor involvement, AST less than or equal to 5 times ULN and ALT less than or equal to 5 times ULN are acceptable. Patients may have endoscopic or radiologic stenting to treat biliary obstructions. If so, then bilirubin must return to less than or equal to 1.5 times ULN and ALP, AST, and ALT to less than or equal to 5 times ULN prior to enrollment. Renal: serum creatinine within normal limits, less than or equal to 1.5 times ULN.
  • Have a performance status of less than or equal to 2 on the Eastern Cooperative Oncology Group (ECOG) scale
  • Patients must have recovered from any Grade 3/4 toxicities of previous therapies
  • Are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures
  • Prior radiation therapy for treatment of cancer is allowed to <25% of the bone marrow, and patients must have recovered from the acute toxic effects of their treatment prior to study enrollment. Prior radiation to the whole pelvis is not allowed. Prior radiotherapy must be completed at least 4 weeks before study entry.
  • Male and female patients with reproductive potential must use an approved contraceptive method during and for 3 months after discontinuation of study treatment. Women of childbearing potential must have a negative beta-human chorionic gonadotropin (B-HCG) pregnancy test documented within 14 days prior to treatment. If condoms are used as a barrier contraceptive, a spermicidal agent should be added to ensure that pregnancy does not occur. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.

For Phase 2:

  • Have histological or cytological diagnosis of adenocarcinoma of the pancreas that is locally advanced (Stage II, III) or metastatic (Stage IV) and not amenable to resection with curative intent. Patients with previous radical surgery for pancreatic cancer are eligible after progression is documented. If they received adjuvant chemotherapy or chemoradiotherapy with gemcitabine, they can be enrolled if the treatment was completed 3 months before or longer
  • Tumor tissue or unstained slides are available from original biopsy or resection or other tumor biopsies
  • Patients may have received previous adjuvant treatment with gemcitabine with or without radiotherapy for pancreatic cancer. Adjuvant treatment must have finished at least 6 months before enrolling.

Exclusion Criteria: Patients will be excluded from the study if they meet any of the following criteria:

  • Are currently enrolled in, or discontinued within the last 30 days from, a clinical trial involving an investigational product or unapproved use of a drug or device (other than the investigational product used in this study), or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study
  • Have moderate or severe cardiac disease:
  • Myocardial infarction within 6 months prior to study entry, unstable angina pectoris, New York Heart Association (NYHA) Class III/IV congestive heart failure, or uncontrolled hypertension
  • Major abnormalities documented by echocardiography with Doppler (for example, moderate or severe heart valve function defect and/or left ventricular ejection fraction (LVEF) <50%, evaluation based on the institutional lower limit of normal)
  • Predisposing conditions that are consistent with development of aneurysms of the ascending aorta or aortic stress (for example, family history of aneurysms, Marfan-Syndrome, bicuspid aortic valve, evidence of damage to the large vessels of the heart documented by CT scan or MRI with contrast)
  • Are unable to swallow tablets or capsules
  • Are pregnant or breastfeeding
  • Have any significant medical illnesses that, in the investigator's opinion, cannot be adequately controlled with appropriate therapy or would compromise the patient's ability to tolerate this therapy
  • Have a history of any other cancer (except non-melanoma skin cancer or carcinoma in-situ), unless in complete remission and off of all therapy for that disease for a minimum of 3 years
  • Have active infection that would interfere with the study objectives or influence study compliance
  • Phase 2 only: Endocrine pancreatic tumors or ampullary cancer
  • Patients with acute or chronic leukemia or with any other disease likely to have a significant bone marrow infiltration (screening not required)
  • Have previously completed or withdrawn from this study or any other study investigating LY2157299 or any other TGF-ß inhibitor
  • Have known allergy to LY2157299 or gemcitabine or any ingredient of LY2157299 or gemcitabine formulations
Both
18 Years and older
No
Contact: There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559
United States,   Belgium,   France,   Germany,   Italy,   Spain
 
NCT01373164
13663, H9H-MC-JBAJ
No
Eli Lilly and Company
Eli Lilly and Company
Not Provided
Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) Eli Lilly and Company
Eli Lilly and Company
April 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP